Abstract
IntroductionSerum sclerostin is a protein inhibitor of the wingless signaling pathway of bone formation whose role in osteoimmunology and inflammatory arthritides is still controversial.AimThe aim of the present study was to examine the relation of serum sclerostin as one member of the wingless signal protein inhibitors to arthritic and bony manifestation of psoriasis as a model of autoimmune inflammatory arthritis.Settings and designThis was a cross-sectional, prospective study.Patients and methodsThe study included 30 psoriatic arthritis (PsA) male patients whose mean age was 43.3±8.3 years and had a disease duration of 3.8±2.6 years, and 15 age-matched and sex-matched apparently healthy controls. Serum sclerostin was measured using the enzyme-linked immunosorbent assay. Disease activity was measured using the Disease Activity Index for Psoriatic Arthritis. Ultrasonography of enthesis at Leeds enthesitis sites and dual energy X-ray absorptiometry at the lumbar spine were also carried out for all patients.Statistical analysisThe independent t-test, Pearson’s correlation coefficient, and one-way analysis of variance were used for statistical analysis.ResultsThe serum sclerostin level was significantly higher in PsA patients compared with controls, with a mean of 0.64 and 0.37 ng/ml, respectively. Serum sclerostin correlated significantly with Disease Activity Index for Psoriatic Arthritis, ultrasonography inflammatory and damage scores, and dual energy X-ray absorptiometry at the lumbar spine.ConclusionSerum sclerostin could have a significant role in the development of inflammation-associated bone damage in PsA. Further follow-up studies are recommended to confirm the role of serum sclerostin in inflammation and bone damage in PsA patients and the factors that could regulate this autoimmune pathological event.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call